$ABT · Abbott Laboratories
This filing is a Form 4, which is a standard SEC document that reports changes in beneficial ownership by company insiders. It was filed by Nita Ahuja, a director of Abbott Laboratories, for a transaction dated September 30, 2026. The filing covers a change in derivative securities, specifically stock equivalent units, rather than a direct purchase or sale of common stock.
According to the filing, Ms. Ahuja acquired 318 stock equivalent units at a price of $98.83 per unit. These units represent director fees that were credited to a stock equivalent unit account. The footnotes explain that these units earn the same return as if the fees were invested in Abbott common shares, and they are generally paid out in cash at age 65 or upon retirement from the board. This is a routine compensation arrangement for board members rather than an open-market transaction.
Following the reported transaction, Ms. Ahuja beneficially owned 771 stock equivalent units directly. The balance also includes additional units acquired through a dividend reinvestment feature. No non-derivative securities, such as common stock, were acquired or disposed of in this filing.